Skip to main content

Table 6 Adverse events in 72 patients on Alirocumab 75 or 150 mg, or Evolocumab 140 mg, by treatment regimens

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

 

All 3 treatment groups (n = 72) F45, M27 Follow up length median 25 weeks

Alirocumab 75 mg (n = 25) F12, M13 Follow up length median 24 weeks

Alirocumab 150 mg (n = 15) F10, M5 Follow up length median 26 weeks

Evolocumab 140 mg (n = 32) F23, M9 Follow up length median 24 weeks

Flu-like myositis

8 (10%)

1 (4%)

5 (33%)

2 (6%)

Respiratory tract infection/symptoms

6 (8%)

1 (4%)

1 (7%)

4 (13%)

Inject site reaction

4 (6%)

1 (4%)

1 (7%)

2 (6%)

Fatigue

1 (1%)

1 (4%)

  

Headache/mental acuity/mood

2 (3%)

 

1 (7%)

1 (3%)

Urticaria/itchiness

2 (3%)

1 (4%)

 

1 (3%)

G.I. symptom

2 (3%)

 

1 (7%)

1 (3%)

Weight gain

1 (1%)

  

1 (3%)

Hair loss

1 (1%)

  

1 (3%)

Any adverse events

22 (31%)

5 (20%)

7 (47%)

10 (31%)

No adverse events

50 (69%)

20 (80%)

8 (53%)

22 (69%)

  1. Comparing adverse events (any vs none), no difference among 3 treatment groups (Fisher’s p > .05)